Alx Oncology Holdings (ALXO) Return on Invested Capital (2020)

Alx Oncology Holdings (ALXO) reported Return on Invested Capital of 0.04% for Q4 2020, up 2.39% sequentially from 0.04% in Q3 2020.

Alx Oncology Holdings (ALXO) Return on Invested Capital (2020) Analysis & Trends

Alx Oncology Holdings (ALXO) has 1 years of Return on Invested Capital data on file, last reported at 0.04% in Q4 2020.

For the quarter ending Q4 2020, Return on Invested Capital changed N/A year-over-year to 0.04%; the trailing twelve-month figure through Dec 2020 stood at 0.04% (changed N/A YoY), and the FY2022 full-year result was 0.76%, changed N/A from the prior year.
Return on Invested Capital rose to 0.04% in Q4 2020, from 0.04% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.04% in Q4 2020 to a low of 0.04% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alx Oncology Holdings	211.24 Mn	211.24 Mn	-	-

Download Data

Date	Value
Dec 31, 2020	-0.04%
Sep 30, 2020	-0.04%